Ebselen is under clinical development by Sound Pharmaceuticals and currently in Phase II for Drug Toxicity. According to GlobalData, Phase II drugs for Drug Toxicity have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ebselen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ebselen overview
SPI-1005 (ebselen) is under development for the treatment of bipolar disorder, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mild to moderate noise-induced hearing loss (auditory threshold shift), Meniere's disease, and aminoglycoside-induced ototoxicity. The drug candidate is administered orally. It is a small molecule mimic of the enzyme glutathione peroxidase (Gpx). GPx is the dominant catalytic antioxidant enzyme that presents in the cochlea. it was also under development for chemotherapy in head and neck or non-small cell lung cancer induced hearing loss and tinnitus.
Sound Pharmaceuticals overview
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops therapeutics for sensorineural otologic diseases. The company develops drugs designed to regenerate cells within the cochlea and restore hearing for individuals with severe to profound hearing loss. SPI’s product pipeline includes SPI-1005, a proprietary oral formulation of ebselen for treating acute noise-induced hearing loss and Meniere’s disease, and SPI-3005 a chemoprotection for tinnitus. and SPI-5557 a deafness regeneration. It also conducts preclinical models of hearing loss and tinnitus. SPI is headquartered in Seattle, Washington, the US.
For a complete picture of Ebselen’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
